- Home
- TC vs REVB Comparison
TC vs REVB Comparison
Compare TC & REVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TC
- REVB
- Stock Information
- Founded
- TC 2010
- REVB 2020
- Country
- TC China
- REVB United States
- Employees
- TC N/A
- REVB N/A
- Industry
- TC Business Services
- REVB Biotechnology: Pharmaceutical Preparations
- Sector
- TC Consumer Discretionary
- REVB Health Care
- Exchange
- TC Nasdaq
- REVB Nasdaq
- Market Cap
- TC 2.4M
- REVB 2.6M
- IPO Year
- TC 2018
- REVB N/A
- Fundamental
- Price
- TC $0.76
- REVB $0.82
- Analyst Decision
- TC
- REVB
- Analyst Count
- TC 0
- REVB 0
- Target Price
- TC N/A
- REVB N/A
- AVG Volume (30 Days)
- TC 544.5K
- REVB 233.7K
- Earning Date
- TC 06-10-2025
- REVB 05-08-2025
- Dividend Yield
- TC N/A
- REVB N/A
- EPS Growth
- TC N/A
- REVB N/A
- EPS
- TC N/A
- REVB N/A
- Revenue
- TC $6,737,269.00
- REVB N/A
- Revenue This Year
- TC N/A
- REVB N/A
- Revenue Next Year
- TC N/A
- REVB N/A
- P/E Ratio
- TC N/A
- REVB N/A
- Revenue Growth
- TC N/A
- REVB N/A
- 52 Week Low
- TC $0.46
- REVB $0.77
- 52 Week High
- TC $4.30
- REVB $60.80
- Technical
- Relative Strength Index (RSI)
- TC 55.96
- REVB 16.59
- Support Level
- TC $0.74
- REVB $0.83
- Resistance Level
- TC $0.86
- REVB $2.68
- Average True Range (ATR)
- TC 0.09
- REVB 0.25
- MACD
- TC 0.00
- REVB -0.23
- Stochastic Oscillator
- TC 51.33
- REVB 1.88
About TC TuanChe Limited
Token Cat Ltd is an omnichannel automotive marketplace in China. The company operates in one segment, providing auto shows, special promotion event services, virtual dealerships, online marketing services, and more. It organizes auto shows to facilitate transactions between consumers and auto dealers, which include auto dealers, automakers, and automotive service providers. It offers services through its online platform and offline events.
About REVB Revelation Biosciences Inc.
Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).